Skip to main content

Table 1 Patient characteristics of the mGC cohort overall and stratified by disease-specific untreated, disease-specific treated, and lines of treatment

From: Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany

 

mGCc

(n = 5,278)

Disease-specific untreatedc

(n = 2,649)

Disease-specific treatedc

(n = 2,629)

1LOTd

(n = 2,629)

2LOTd

(n = 861)

3LOTd

(n = 268)

Age, mean (SD)

72.7 (11.6)

77.4 (10.2)

68.1 (11.0)

68.3 (11.0)

66.8 (11.3)

66.3 (11.5)

Sex

Female, n (%)

2,013 (38.1)

1,126 (42.5)

887 (33.7)

887 (33.7)

259 (30.1)

78 (29.1)

Male, n (%)

3,265 (61.9)

1,523 (57.5)

1,742 (66.3)

1,742 (66.3)

602 (69.9)

190 (70.9)

Charlson Comorbidity Index scorea, mean (SD)b

3.0 (2.5)

3.7 (2.6)

2.3 (2.2)

2.4 (2.2)

2.2 (2.1)

1.9 (2.0)

Number of hospitalizationsa, mean (SD)

2.0 (1.9)

2.1 (1.8)

1.9 (2.0)

2.6 (2.0)

4.6 (4.6)

3.3 (3.0)

  1. a12-month period pre-index date or pre-starting the treatment line (incl. index date or start date for LOT); bMetastatic solid tumor diagnosis at index (ICD-10: C77-C80) and gastric cancer (ICD-10: C16) diagnosis were excluded for the CCI score; cPatients characteristics at time of diagnosis; dPatients characteristics at the start of each line of treatment